Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation

[1]  P. Syrris,et al.  The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[3]  E. Schuetz,et al.  Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  C. Staatz,et al.  Bayesian Forecasting and Prediction of Tacrolimus Concentrations in Pediatric Liver and Adult Renal Transplant Recipients , 2003, Therapeutic drug monitoring.

[5]  C. Staatz,et al.  Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  Y. Cheung,et al.  Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. , 2003, Pharmacogenetics.

[7]  P. Syrris,et al.  Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement , 2002, Transplantation.

[8]  T. Pisitkun,et al.  The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. , 2002, Transplantation proceedings.

[9]  C. Staatz,et al.  Population pharmacokinetics of tacrolimus in adult kidney transplant recipients , 2002, Clinical pharmacology and therapeutics.

[10]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[11]  S. McCann,et al.  Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry , 2002, Annals of clinical biochemistry.

[12]  N. Undre,et al.  Pharmacokinetics of tacrolimus in heart transplantation. , 2002, Transplantation proceedings.

[13]  P. Koefoed-Nielsen,et al.  Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. , 2002, Transplantation proceedings.

[14]  Miyuki Kimura,et al.  Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein , 2002, Clinical pharmacology and therapeutics.

[15]  I. Colle,et al.  Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults? , 2002, Transplantation proceedings.

[16]  C. Felipe,et al.  The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring , 2002, Clinical transplantation.

[17]  N. Undre,et al.  Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. , 2002, Transplantation proceedings.

[18]  N. Undre,et al.  Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. , 2002, Transplantation proceedings.

[19]  M. Christiaans,et al.  Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients. , 2002, Transplantation proceedings.

[20]  K. Uchida,et al.  Optimal use of tacrolimus in living donor renal transplantation in children. , 2002, Transplantation proceedings.

[21]  J. Poulsen,et al.  C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  T. Nabeshima,et al.  Interference of Hematocrit in the Tacrolimus II Microparticle Enzyme Immunoassay , 2002, Therapeutic drug monitoring.

[23]  N. Goto,et al.  Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. , 2002, Transplantation proceedings.

[24]  E. Schütz,et al.  Therapeutic drug monitoring of tacrolimus early after liver transplantation. , 2002, Transplantation proceedings.

[25]  K. Takahashi,et al.  Study of pharmacokinetic parameters of tacrolimus by different oral administration periods in renal transplantation. , 2002, Transplantation proceedings.

[26]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[27]  G. Mazariegos,et al.  Pediatric intestinal transplantation: Historical notes, principles and controversies , 2002, Pediatric transplantation.

[28]  M. Oellerich,et al.  Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. , 2002, Clinical chemistry.

[29]  J. Hooff,et al.  Evaluation of prediction of tacrolimus area under the curve by trough concentrations , 2002 .

[30]  K. Resch,et al.  Simultaneous Quantification of Sirolimus, Everolimus, Tacrolimus and Cyclosporine by Liquid Chromatography-Mass Spectrometry (LC-MS) , 2002, Clinical chemistry and laboratory medicine.

[31]  M. Makuuchi,et al.  Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation , 2002, Clinical transplantation.

[32]  D. Gerber,et al.  Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[33]  Nancy M. Stolpman,et al.  Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[34]  Atholl Johnston,et al.  Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. , 2002, Clinical therapeutics.

[35]  B. Bouzas,et al.  Replacement of cyclosporine by tacrolimus for immunosuppression in heart transplant patients: safety and efficacy. , 2002, Transplantation proceedings.

[36]  J. Poulsen,et al.  Blood Tacrolimus Levels and Calcineurin Phosphatase Activity Early after Renal Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  A. Tzakis,et al.  Intestinal and Multivisceral Transplantation , 2002, World Journal of Surgery.

[38]  E. Granot,et al.  Abrupt increase of tacrolimus blood levels during an episode of Shigella infection in a child after liver transplantation. , 2001, Therapeutic drug monitoring.

[39]  M. Kaneko,et al.  Effect of ascites on tacrolimus disposition in a liver transplant recipient. , 2001, Therapeutic drug monitoring.

[40]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[41]  R. Gaston.  Maintenance immunosuppression in the renal transplant recipient: an overview. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  J. Poulsen,et al.  Optimal time for determination of blood tacrolimus level. , 2001, Transplantation proceedings.

[43]  M. Kimikawa,et al.  Effective oral administration of tacrolimus in renal transplant recipients , 2001, Clinical transplantation.

[44]  C. Staatz,et al.  Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. , 2001, Transplantation.

[45]  P Taylor,et al.  Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  H. Saito,et al.  Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation , 2001, European Journal of Clinical Pharmacology.

[47]  J. Fung,et al.  Quantitation of Immunosuppression by Tacrolimus Using Flow Cytometric Analysis of Interleukin-2 and Interferon-&ggr; Inhibition in CD8− and CD8+ Peripheral Blood T Cells , 2001, Therapeutic drug monitoring.

[48]  E. Hochleitner,et al.  Increased tacrolimus levels during diarrhea , 2001, Transplant international : official journal of the European Society for Organ Transplantation.

[49]  B. Meiser,et al.  Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[50]  T. Habuchi,et al.  Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration , 2001, International journal of urology : official journal of the Japanese Urological Association.

[51]  I. Bekersky,et al.  Comparative Tacrolimus Pharmacokinetics: Normal versus Mildly Hepatically Impaired Subjects , 2001, Journal of clinical pharmacology.

[52]  A. Okada,et al.  Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation , 2001, Pediatric transplantation.

[53]  S. Soldin,et al.  Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography--tandem mass-spectrometry. , 2001, Clinical biochemistry.

[54]  G. Lensmeyer,et al.  Therapeutic Monitoring of Tacrolimus Concentrations in Blood: Semi-Automated Extraction and Liquid Chromatography-Electrospray Ionization Mass Spectrometry , 2001, Therapeutic drug monitoring.

[55]  Julie A. Johnson,et al.  THE EFFECT OF GUT METABOLISM ON TACROLIMUS BIOAVAILABILITY IN RENALTRANSPLANT RECIPIENTS1,2 , 2001, Transplantation.

[56]  H. Saito,et al.  Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living‐donor liver transplantation , 2001, Clinical pharmacology and therapeutics.

[57]  R. Morris,et al.  New approach in drug development: whole blood pharmacodynamic assays reflect biological activities of tacrolimus. , 2001, Transplantation proceedings.

[58]  M. de Bonis,et al.  Tacrolimus as a rescue immunosuppressant after heart transplantation. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[59]  L. Shaw,et al.  Clinical Utility of Monitoring Tacrolimus Blood Concentrations in Liver Transplant Patients , 2001, Journal of clinical pharmacology.

[60]  C. Campañá,et al.  Pharmacokinetics of tacrolimus during the early phase after heart transplantation. , 2001, Transplantation proceedings.

[61]  H. Reichenspurner,et al.  Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[62]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[63]  R. Jelliffe,et al.  Failure of Traditional Trough Levels to Predict Tacrolimus Concentrations , 2001, Therapeutic drug monitoring.

[64]  J. Thompson,et al.  Tacrolimus and diarrhea: Pathogenesis of altered metabolism , 2001, Pediatric transplantation.

[65]  J. Pirsch,et al.  Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients , 2001, Pediatric transplantation.

[66]  R. Margreiter,et al.  Rotavirus infection as cause of tacrolimus elevation in solid‐organ‐transplanted children , 2001, Pediatric transplantation.

[67]  B. Simma,et al.  Elevated tacrolimus trough levels in association with mycophenolate mofetil‐induced diarrhea: A case report , 2001, Pediatric transplantation.

[68]  M. Ingelman-Sundberg,et al.  Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. , 2001, Biochemical and biophysical research communications.

[69]  I. Bekersky,et al.  Effect of Time of Meal Consumption on Bioavailability of a Single Oral 5 mg Tacrolimus Dose , 2001, Journal of clinical pharmacology.

[70]  U. Brinkmann,et al.  Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. , 2001, Pharmacogenetics.

[71]  M. Mehra,et al.  Ethnic disparities in the pharmacologic characteristics of tacrolimus in heart transplantation. , 2001, Transplantation proceedings.

[72]  C. Felipe,et al.  Choosing the right dose of new immunossuppressive drugs for new populations: importance of pharmacokinetic studies. , 2001, Transplantation proceedings.

[73]  P. Berloco,et al.  Tacrolimus as cornerstone immunosuppressant in kidney transplantation. , 2001, Transplantation proceedings.

[74]  W. V. van Son,et al.  Prediction of the inhibition of IL-2 production by calcineurin inhibitors. , 2001, Transplantation proceedings.

[75]  H. Asanuma,et al.  Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. , 2001, Transplantation proceedings.

[76]  V. Armstrong,et al.  New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. , 2001, Clinical biochemistry.

[77]  I. Bekersky,et al.  Effect of Low‐ and High‐Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects , 2001, Journal of clinical pharmacology.

[78]  M. Slooff,et al.  Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. , 2001, Transplantation proceedings.

[79]  J. Halpert,et al.  cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. , 2001, Molecular pharmacology.

[80]  C. Manzanares,et al.  Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion Therapy , 2001, Clinical Pharmacokinetics.

[81]  U. Christians,et al.  The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups , 2001, Clinical pharmacology and therapeutics.

[82]  Paul J. Williams,et al.  The Role of Population Pharmacokinetics in Drug Development in Light of the Food and Drug Administration’s ‘Guidance for Industry: Population Pharmacokinetics’ , 2000, Clinical pharmacokinetics.

[83]  S. Chan,et al.  Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. , 2000, British journal of clinical pharmacology.

[84]  Po-Huang Lee,et al.  Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. , 2000, Transplantation proceedings.

[85]  M. Makuuchi,et al.  Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation. , 2000, Transplantation Proceedings.

[86]  R. Morris,et al.  Pharmacodynamics of immunosuppressive drugs. , 2000, Current opinion in immunology.

[87]  P. Taylor,et al.  Simultaneous Quantification of Tacrolimus and Sirolimus, in Human Blood, by High-Performance Liquid Chromatography–Tandem Mass Spectrometry , 2000, Therapeutic drug monitoring.

[88]  M. Manns,et al.  Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[89]  S. Hilsenbeck,et al.  Tacrolimus clearance is age-dependent within the pediatric population , 2000, Bone Marrow Transplantation.

[90]  V. Furlan,et al.  Conversion from cyclosporin A to tacrolimus in pediatric liver transplantation , 2000, Pediatric transplantation.

[91]  P. Halloran,et al.  Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. , 2000, Transplantation.

[92]  G. Yanik,et al.  Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation , 2000, Bone Marrow Transplantation.

[93]  S. Uemoto,et al.  Effect of intestinal P‐glycoprotein on daily tacrolimus trough level in a living‐donor small bowel recipient , 2000, Clinical pharmacology and therapeutics.

[94]  G. Mazariegos,et al.  Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. , 2000, Transplantation.

[95]  R. Jindal,et al.  Towards a specific immunosuppression for pancreas and islet grafts , 2000, Clinical transplantation.

[96]  R. J. Dumont,et al.  Methods for Clinical Monitoring of Cyclosporin in Transplant Patients , 2000, Clinical pharmacokinetics.

[97]  C. Shek,et al.  Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[98]  J. Fung,et al.  QUANTITATION OF IMMUNOSUPPRESSION BY FK506 USING FLOW CYTOMETRIC ANALYSIS OF IL‐2 AND INF‐&ggr; INHIBITION IN PERIPHERAL BLOOD T CELLS.: Abstract# 1081 , 2000 .

[99]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[100]  L. Kennedy,et al.  Tacrolimus: An Alternative for Graft-Versus-Host Disease Prevention , 2000, The Annals of pharmacotherapy.

[101]  G. Plosker,et al.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. , 2000, Drugs.

[102]  M. Christensen,et al.  Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea , 2000, Pediatric transplantation.

[103]  G. Kearns,et al.  Cytochrome P450 3A , 1999, Clinical pharmacokinetics.

[104]  J. Wingard,et al.  Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation , 1999, Bone Marrow Transplantation.

[105]  M. Christiaans,et al.  Dosing and management guidelines for tacrolimus in renal transplant patients. , 1999, Transplantation proceedings.

[106]  M. Rela,et al.  Oral absorption of tacrolimus in children with intestinal failure due to short or absent small bowel , 1999, Transplant international : official journal of the European Society for Organ Transplantation.

[107]  Y Zhang,et al.  Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[108]  A. Mayer.  Four-year follow-up of the European Tacrolimus Multicenter Renal Study. , 1999, Transplantation proceedings.

[109]  G. Burckart,et al.  P‐glycoprotein and Drug Therapy in Organ Transplantation , 1999, Journal of clinical pharmacology.

[110]  L. Rostaing,et al.  Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients , 1999, Clinical transplantation.

[111]  L. Shaw,et al.  Current opinions on therapeutic drug monitoring of immunosuppressive drugs. , 1999, Clinical therapeutics.

[112]  R. Shapiro,et al.  Tacrolimus in solid organ transplantation: an update. , 1999, Transplantation proceedings.

[113]  G. Tydén,et al.  Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. , 1999, British journal of clinical pharmacology.

[114]  J. Briegel,et al.  Optimization of the immunosuppressive protocol after lung transplantation. , 1999, Transplantation.

[115]  F. J. Fricker,et al.  Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. , 1999, The Journal of Heart and Lung Transplantation.

[116]  J. Briegel,et al.  Tacrolismus (FK506) as Primary Immunosuppressant After Lung Transplantation , 1999 .

[117]  N. Undre,et al.  The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[118]  S. Yamaguchi,et al.  No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. , 1999, Biochemical pharmacology.

[119]  Cherylee W. J. Chang.  Neurologic complications of critical illness and transplantation , 1999 .

[120]  D. Renlund,et al.  A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[121]  B. Griffith,et al.  Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. , 1999 .

[122]  J. Fay,et al.  Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[123]  M. Henry.  Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles , 1999, Clinical transplantation.

[124]  E. Trulock,et al.  Suggested guidelines for the use of tacrolimus in lung-transplant recipients. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[125]  J. Hooff,et al.  Low systemic exposure to tacrolimus correlates with acute rejection. , 1999, Transplantation proceedings.

[126]  R. Stratta.  Optimal immunosuppression in pancreas transplantation. , 1999, Transplantation proceedings.

[127]  C. Esquivel,et al.  Long‐term outcomes in pediatric liver recipients: Comparison between cyclosporin A and tacrolimus , 1999, Pediatric transplantation.

[128]  E. Arbustini,et al.  Clinical pharmacokinetics of tacrolimus in heart transplant recipients. , 1999, Therapeutic drug monitoring.

[129]  M. Abecassis,et al.  Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. , 1999, Transplantation.

[130]  R. M. Fisher,et al.  Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers , 1999, Journal of clinical pharmacology.

[131]  J. Pirsch,et al.  The role of tacrolimus in adult kidney transplantation: a review. , 1998, Clinical transplantation.

[132]  R. Shapiro,et al.  Tacrolimus in pediatric renal transplantation: a review. , 1998, Pediatric transplantation.

[133]  Y Zhang,et al.  Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. , 1998, Journal of pharmaceutical sciences.

[134]  S. Kawasaki,et al.  Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. , 1998, Transplantation.

[135]  T. Starzl,et al.  Pediatric renal transplantation under tacrolimus-based immunosuppression. , 1998, Transplantation.

[136]  T. Schnider,et al.  Expanding clinical applications of population pharmacodynamic modelling. , 1998, British journal of clinical pharmacology.

[137]  R. Yatscoff,et al.  The monitoring of immunosuppressive drugs: a pharmacodynamic approach. , 1998, Therapeutic drug monitoring.

[138]  A. Nademanee,et al.  Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.

[139]  T. Starzl,et al.  LONG-TERM RESULTS OF PANCREAS TRANSPLANTATION UNDER TACROLIMUS IMMUNOSUPPRESSION , 1998 .

[140]  P. Jara,et al.  Monitoring of tacrolimus as rescue therapy in pediatric liver transplantation. , 1998, Therapeutic drug monitoring.

[141]  R. Busuttil,et al.  Tacrolimus is superior to cyclosporine in liver transplantation. , 1998, Transplantation proceedings.

[142]  P. Halloran,et al.  Calcineurin and the biological effect of cyclosporine and tacrolimus. , 1998, Transplantation proceedings.

[143]  A. Davenport,et al.  Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. , 1998, Transplantation proceedings.

[144]  L. Benet.  Impact of intraindividual variability of drugs on therapeutic outcomes: lessons from outside transplantation. , 1998, Transplantation proceedings.

[145]  G. Patterson,et al.  Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[146]  Nicholas H. G. Holford,et al.  Population Pharmacokinetics and Pharmacodynamics: An Underutilized Resource , 1998 .

[147]  L. Shaw,et al.  THERAPEUTIC DRUG MONITORING OF CYCLOSPORINE AND TACROLIMUS , 1998 .

[148]  T. Starzl,et al.  Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. , 1998, Transplantation proceedings.

[149]  J. Barkun,et al.  Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. , 1998, Transplantation proceedings.

[150]  G. Ramadori,et al.  Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. , 1998, Transplantation proceedings.

[151]  J. Fung,et al.  Comparison of Tacrolimus Absorption in Transplant Patients Receiving Continuous versus Interrupted Enteral Nutritional Feeding , 1998, The Annals of pharmacotherapy.

[152]  I. Bekersky,et al.  Demographic considerations in tacrolimus pharmacokinetics. , 1998, Transplantation proceedings.

[153]  J. Neylan.  Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. , 1998, Transplantation proceedings.

[154]  P. Stock,et al.  Suggested guidelines for the use of tacrolimus in pancreas/kidney transplantation. , 1998, Clinical transplantation.

[155]  M. Yacoub,et al.  Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. , 1998, Transplantation proceedings.

[156]  J. Segura,et al.  Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. , 1998, Transplantation proceedings.

[157]  H. Palevsky,et al.  Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. , 1998, Transplantation proceedings.

[158]  W. V. van Son,et al.  Quantification of immunosuppression by flow cytometric measurement of intracellular cytokine synthesis , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[159]  W. Padberg,et al.  Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. , 1998, Transplantation proceedings.

[160]  T. Miki,et al.  Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation , 1998 .

[161]  M. Brunet,et al.  Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[162]  T. Starzl,et al.  Incidence Of End-Stage Renal Failure Amongst Long-term Survival Of Primary Liver Transplant Recipients Under Tacrolimus: Adults and Children , 1998 .

[163]  D. Min,et al.  An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. , 1998, Therapeutic drug monitoring.

[164]  M. Moxey-Mims,et al.  Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) , 1998, Transplantation.

[165]  A. Trull.  Therapeutic Monitoring of Tacrolimus , 1998, Annals of clinical biochemistry.

[166]  J. Skyler,et al.  Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. , 1998, Transplantation proceedings.

[167]  J. Neylan.  Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. , 1998, Transplantation.

[168]  A. Gaber,et al.  Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. , 1998, Transplantation.

[169]  A. Grygotis,et al.  High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants. , 1997, Therapeutic drug monitoring.

[170]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[171]  K. Goa,et al.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. , 1997, Drugs.

[172]  H. Antunes,et al.  Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. , 1997, Transplantation.

[173]  J. Farrant,et al.  Determination of intracellular cytokines by flow-cytometry following whole-blood culture. , 1997, Journal of immunological methods.

[174]  B. Erbslöh-Möller,et al.  Effect of FK506 on magnesium homeostasis after renal transplantation. , 1997, Transplantation proceedings.

[175]  Hébert.  Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. , 1997, Advanced drug delivery reviews.

[176]  A. Alak,et al.  An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay. , 1997, Journal of pharmaceutical and biomedical analysis.

[177]  Morton B. Brown,et al.  Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.

[178]  T. Starzl,et al.  Pregnancy after liver transplantation under tacrolimus. , 1997, Transplantation.

[179]  J. Squifflet,et al.  Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection - A report of the European Tacrolimus Multicenter Renal Study Group , 1997 .

[180]  A. Alak,et al.  Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. , 1997, Transplantation proceedings.

[181]  R. Gruessner,et al.  Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. , 1997, Clinical transplantation.

[182]  Q. Zhang,et al.  A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry. , 1997, Therapeutic drug monitoring.

[183]  R. Wiesner,et al.  Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[184]  Joshua Miller,et al.  A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .

[185]  R. Jindal,et al.  Post-Transplant Diabetes Mellitus , 1997, Drug safety.

[186]  C. Mignat,et al.  Clinically Significant Drug Interactions with New Immunosuppressive Agents , 1997, Drug safety.

[187]  W. Bechstein,et al.  Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. , 1997, Clinical transplantation.

[188]  S. Kawasaki,et al.  Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation , 1996, Acta paediatrica Japonica : Overseas edition.

[189]  A. Fabrega,et al.  Circadian variation of tacrolimus disposition in liver allograft recipients. , 1996, Transplantation.

[190]  A. Matas,et al.  An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. , 1996, Transplantation.

[191]  R. Kershner,et al.  Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. , 1996, Transplantation.

[192]  G. Wilkinson.  Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans , 1996, Journal of pharmacokinetics and biopharmaceutics.

[193]  B. Ring,et al.  The human drug metabolizing cytochromes P450 , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[194]  U. Christians,et al.  Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. , 1996, Clinical chemistry.

[195]  H. Koeppen,et al.  Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. , 1996, Transplantation.

[196]  P. Neuhaus,et al.  Two‐year data from the European multicentre tacrolimus (F 06) liver study , 1996, Transplant international : official journal of the European Society for Organ Transplantation.

[197]  Y. Yamaoka,et al.  Pharmacokinetics of FK 506 in living-related liver transplantation. , 1996, Transplantation proceedings.

[198]  C. Esquivel,et al.  Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. , 1996, Transplantation.

[199]  R. Collins,et al.  FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. , 1996, Blood.

[200]  B. Griffith,et al.  Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. , 1996, Transplantation proceedings.

[201]  R. Stratta,et al.  FK 506 induction and rescue therapy in pancreas transplant recipients. , 1996, Transplantation proceedings.

[202]  U. Christians,et al.  Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber , 1996, British journal of pharmacology.

[203]  P. Colombani,et al.  Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. , 1996, Transplantation.

[204]  G. Klintmalm,et al.  General guidelines for the use of tacrolimus in adult liver transplant patients. , 1996, Transplantation.

[205]  U. Christians,et al.  Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. , 1996, British journal of clinical pharmacology.

[206]  M. A. Moseley,et al.  CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[207]  P. Halloran,et al.  Molecular mechanisms of new immunosuppressants. , 1996, Clinical transplantation.

[208]  F. Aweeka,et al.  The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy , 1996, Clinical pharmacokinetics.

[209]  Y. Yamaoka,et al.  The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. , 1996, Transplantation.

[210]  D. Metcalfe,et al.  Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. , 1995, Journal of immunological methods.

[211]  W. Jusko.  Analysis of Tacrolimus (FK 506) in Relation to Therapeutic Drug Monitoring , 1995, Therapeutic drug monitoring.

[212]  A. Thomson,et al.  Mode of Action of Tacrolimus (FK506): Molecular and Cellular Mechanisms , 1995, Therapeutic drug monitoring.

[213]  U. Christians,et al.  Consensus Document: Therapeutic Monitoring of Tacrolimus (FK‐506) , 1995 .

[214]  T. Starzl,et al.  Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.

[215]  P. Mcmaster,et al.  Therapeutic Drug Monitoring of Tacrolimus in Clinical Transplantation , 1995, Therapeutic drug monitoring.

[216]  U. Christians,et al.  Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[217]  L. Makowka,et al.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation: The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994;331:1110–1115 , 1995 .

[218]  V. Maino,et al.  Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. , 1995, Blood.

[219]  D. Ellis.  Clinical use of tacrolimus (FK-506) in infants and children with renal transplants , 1995, Pediatric Nephrology.

[220]  T. Starzl,et al.  133 PHARMACOKINETICS OF TACROLIMUS (TAC) IN TRANSPLANT PATIENTS , 1995 .

[221]  R. Venkataramanan,et al.  Tacrolimus: a new immunosuppressive agent. , 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[222]  U. Christians,et al.  A Risk-Benefit Assessment of Tacrolimus in Transplantation , 1995, Drug safety.

[223]  F. J. Fricker,et al.  Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506. , 1995, Journal of the American College of Cardiology.

[224]  Wojciech Piekoszewski,et al.  Pharmacokinetics of tacrolimus in liver transplant patients , 1995, Clinical pharmacology and therapeutics.

[225]  D. Buell,et al.  FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. , 1995, Transplantation proceedings.

[226]  G. Klintmalm,et al.  Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. , 1995, Transplantation proceedings.

[227]  G. Klintmalm,et al.  Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. , 1995, Transplantation proceedings.

[228]  Y. Yamaoka,et al.  Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. , 1995, Transplantation proceedings.

[229]  U. Christians,et al.  Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. , 1995, Transplantation proceedings.

[230]  G. Gores,et al.  Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue , 1995, Hepatology.

[231]  P. Neuhaus,et al.  Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation , 1994, Transplant international : official journal of the European Society for Organ Transplantation.

[232]  U. Christians,et al.  Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). , 1994, British journal of clinical pharmacology.

[233]  W. Bechstein,et al.  Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. , 1994, Transplantation proceedings.

[234]  Sewing Kf.  Pharmacokinetics, dosing principles, and blood level monitoring of FK506. , 1994 .

[235]  S. Takahara,et al.  Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients. , 1994, Transplantation proceedings.

[236]  B. Karanam,et al.  FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[237]  S. Gruber,et al.  Pharmacokinetics of FK506 After Intravenous and Oral Administration in Patients Awaiting Renal Transplantation , 1994, Journal of clinical pharmacology.

[238]  S. Takahara,et al.  Monitoring of FK 506 blood levels in kidney transplant recipients. , 1994, Transplantation proceedings.

[239]  J. Reyes,et al.  FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. , 1994, Transplantation proceedings.

[240]  A Radbruch,et al.  Flow cytometric determination of cytokines in activated murine T helper lymphocytes: Expression of interleukin‐10 in interferon‐γ and in interleukin‐4‐expressing cells , 1994, European journal of immunology.

[241]  T. Starzl,et al.  FK 506 (Tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. , 1994, Research communications in chemical pathology and pharmacology.

[242]  G. Klintmalm,et al.  FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. , 1994, Transplantation.

[243]  D. F. Roberts,et al.  Age at menarche , 1994, The Lancet.

[244]  K. Noda,et al.  Distribution and Protein Binding of FK506, a Potent Immunosuppressive Macrolide Lactone, in Human Blood and Its Uptake by Erythrocytes , 1994, The Journal of pharmacy and pharmacology.

[245]  P. Beaune,et al.  RELATIONSHIP BETWEEN GRAFT CYTOCHROME P‐450 3A CONTENT AND EARLY MORBIDITY AFTER LIVER TRANSPLANTATION1 , 1993, Transplantation.

[246]  K. Iwasaki,et al.  Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[247]  G. Krejs,et al.  Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. , 1993, Transplantation.

[248]  K. Iwasaki,et al.  Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. , 1993, Research communications in chemical pathology and pharmacology.

[249]  D. Faulds,et al.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. , 1993, Drugs.

[250]  W. Jusko,et al.  Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[251]  T. Starzl,et al.  Pharmacokinetics of FK506 in Liver Transplant Recipients After Continuous Intravenous Infusion , 1993, Journal of clinical pharmacology.

[252]  R. Busuttil,et al.  DIFFERENCES IN ORAL FK506 DOSE REQUIREMENTS BETWEEN ADULT AND PEDIATRIC LIVER TRANSPLANT PATIENTS , 1993, Transplantation.

[253]  C. Heusser,et al.  Detection of intracellular cytokines by flow cytometry. , 1993, Journal of immunological methods.

[254]  S. Uemoto,et al.  EXPERIENCE WITH FK506 IN LIVING‐RELATED LIVER TRANSPLANTATION , 1993, Transplantation.

[255]  T. Starzl,et al.  Two-year experience with FK 506 in pediatric patients. , 1993, Transplantation proceedings.

[256]  H. Schiebel,et al.  Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. , 1992, Clinical chemistry.

[257]  U. Christians,et al.  Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[258]  T. Starzl,et al.  Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. , 1992, Transplantation proceedings.

[259]  A. Gasbarrini,et al.  FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. , 1992, The Italian journal of gastroenterology.

[260]  A H Thomson,et al.  Bayesian Parameter Estimation and Population Pharmacokinetics , 1992, Clinical pharmacokinetics.

[261]  Michael A. Schmidt,et al.  High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. , 1991, Transplantation proceedings.

[262]  M. Kobayashi,et al.  FK 506 assay past and present--characteristics of FK 506 ELISA. , 1991, Transplantation proceedings.

[263]  T. Starzl,et al.  Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. , 1991, Transplantation proceedings.

[264]  W. Jusko,et al.  Monitoring FK 506 concentrations in plasma and whole blood. , 1991, Transplantation proceedings.

[265]  J. Kay,et al.  Uptake of FK 506 by lymphocytes and erythrocytes. , 1991, Transplantation proceedings.

[266]  C. Groth,et al.  Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. , 1991, Transplantation proceedings.

[267]  T. Starzl,et al.  Pharmacokinetics of FK 506 in transplant patients. , 1991, Transplantation proceedings.

[268]  S. Todo,et al.  Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. , 1991, Transplantation proceedings.

[269]  D. V. van Thiel,et al.  Neurologic complications of FK 506. , 1991, Transplantation proceedings.

[270]  G. Kootstra,et al.  FK 506: monitoring in plasma or in whole blood? , 1991, Transplantation proceedings.

[271]  Fung,et al.  Practical aspects of FK 506 analysis (Pittsburgh experience). , 1991, Transplantation proceedings.

[272]  S. Takahara,et al.  Effect of temperature and hematocrit on plasma concentration of FK 506. , 1991, Transplantation proceedings.

[273]  T. Starzl,et al.  Strategy of FK 506 therapy in liver transplant patients: effect of graft function. , 1991, Transplantation proceedings.

[274]  T. Starzl,et al.  THE EFFECT OF GRAFT FUNCTION ON FK506 PLASMA LEVELS, DOSAGES, AND RENAL FUNCTION, WITH PARTICULAR REFERENCE TO THE LIVER , 1991, Transplantation.

[275]  H. Schiebel,et al.  Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. , 1991, Clinical biochemistry.

[276]  S. Todo,et al.  Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. , 1991, Transplantation proceedings.

[277]  T. Starzl,et al.  Use of FK 506 in pediatric patients. , 1991, Transplantation proceedings.

[278]  H. Schiebel,et al.  Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. , 1991, Transplantation proceedings.

[279]  S. Todo,et al.  Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. , 1991, Transplantation proceedings.

[280]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[281]  P. Beaune,et al.  Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. , 1990, The Journal of pharmacology and experimental therapeutics.

[282]  S. Todo,et al.  The effects of FK 506 on renal function after liver transplantation. , 1990, Transplantation proceedings.

[283]  J J Fung,et al.  Pharmacokinetics of FK 506: preclinical and clinical studies. , 1990, Transplantation proceedings.

[284]  S. Todo,et al.  Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. , 1990, Transplantation proceedings.

[285]  J. Schuetz,et al.  Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. , 1989, Archives of biochemistry and biophysics.

[286]  U. Andersson,et al.  Enumeration of IFN-?-producing cells by flow cytometryComparison with fluorescence microscopy , 1988 .

[287]  T. Starzl,et al.  Drug‐Binding Proteins in Liver Transplant Patients , 1988, Journal of clinical pharmacology.

[288]  L. Sheiner,et al.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[289]  Jiunn H. Lin,et al.  Role of P-Glycoprotein in Pharmacokinetics , 2003, Clinical pharmacokinetics.

[290]  D. Holt,et al.  The Pharmacogenetics of Immunosuppression for Organ Transplantation , 2003 .

[291]  T. Gelder.  Drug Interactions with Tacrolimus , 2002 .

[292]  U. Christians,et al.  Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus , 2002, Clinical pharmacokinetics.

[293]  P. Wallemacq,et al.  Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult Patients , 2001, Clinical pharmacokinetics.

[294]  D. Kelly,et al.  Immunosuppressive Drugs in Paediatric Liver Transplantation , 2001, Paediatric drugs.

[295]  Y Zhang,et al.  The Gut as a Barrier to Drug Absorption , 2001, Clinical pharmacokinetics.

[296]  T. Rebbeck,et al.  More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 2000, Journal of the National Cancer Institute.

[297]  J. Hooff,et al.  Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. , 1998, Transplantation proceedings.

[298]  J. Fay,et al.  Tacrolimus pharmacokinetics in BMT patients , 1998, Bone Marrow Transplantation.

[299]  J. Squifflet,et al.  Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. , 1998, Transplantation proceedings.

[300]  N. Undre,et al.  Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. , 1998, Transplantation proceedings.

[301]  J. Hooff,et al.  Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. , 1998, Transplantation proceedings.

[302]  J. Uberti,et al.  Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation , 1998, Bone Marrow Transplantation.

[303]  S. McDiarmid.  The use of tacrolimus in pediatric liver transplantation. , 1998, Journal of pediatric gastroenterology and nutrition.

[304]  T. Bieber,et al.  FK-506/Tacrolimus , 1997 .

[305]  F. Guengerich,et al.  Interactions of FK506 (tacrolimus) with clinically important drugs. , 1996, Research communications in molecular pathology and pharmacology.

[306]  K. Iwasaki,et al.  Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[307]  G. Gores,et al.  Other clinical studyEarly cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue , 1995 .

[308]  D. Steinmuller.  FK506 and organ transplantation , 1994 .

[309]  S. Todo,et al.  FK506 and pregnancy in liver transplant patients. , 1993, Transplantation.

[310]  Nicholls Mg,et al.  The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. , 1990 .

[311]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[312]  A. Karim.  The pharmacokinetics of Norpace. , 1975, Angiology.